Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(naltrexone oral )
841 results
  • A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. [Journal Article]
    Am J Drug Alcohol Abuse 2019; :1-8Sibai M, Mishlen K, … Bisaga A
  • CONCLUSIONS: The results support the feasibility of a week-long outpatient induction onto XR-naltrexone with ascending doses of naltrexone and standing doses of adjunctive medications. By circumventing the need for a protracted period of abstinence and mitigating the severity of withdrawal symptoms experienced during naltrexone titration, this strategy has the potential to increase patient acceptability and access to relapse prevention treatment with XR-naltrexone.
  • Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. [Journal Article]
    Handb Exp Pharmacol 2019Leggio L, Falk DE, … Litten RZ
  • Compared to other medical disorders, including other brain diseases, the number of medications approved for alcohol use disorder (AUD) is very small. Disulfiram, naltrexone (oral and long-acting), and acamprosate are approved by the US Food and Drug Administration (FDA) to treat patients with AUD. These medications are also approved in other countries, including in Europe, where the European Medi…
New Search Next